Answers are grounded in this paper and cite their sources.
Background: Irritant contact dermatitis (ICD) is commonly treated with topical corticosteroids. MAS063D (‘Atopiclair’) is a nonsteroidal effective in atopic dermatitis. Objective: To determine the efficacy of a topical agent, MAS063D, in managing ICD. Methods: Two sites of ICD were created using sodium lauryl sulfate (SLS) in 20 volunteers; MAS063D was then applied to one and a vehicle-only control to the other. Measurements were taken at baseline, 24, 48 and 72 h. Results: The objective measurements of blood flow volume (BFV), skin color (a*) and transepidermal water loss (TEWL) all showed statistically significant benefits of MAS063D over the vehicle-only control. BFV and a* were significantly better at all time points (p = 0.046, p = 0.045, respectively, at 72 h) and TEWL at 48 and 72 h (p = 0.02 at 72 h). Conclusion: MAS063D demonstrated benefits over vehicle in three clinically meaningful outcomes of SLS-induced ICD.
No takes yet. Share an insight, caveat, or question.
Zhai et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: